Your session is about to expire
← Back to Search
Mangafodipir Imaging for Drug-Resistant Epilepsy
Study Summary
This trial is testing if a contrast agent called mangafodipir is better able to show areas of the brain that epilepsy affects. It is for people ages 18-60 who have epilepsy that is not controlled by drugs.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been diagnosed with Parkinson's Disease or Parkinsonism.I am currently taking medication for my blood pressure.I have epilepsy and cannot have surgery.I have experienced psychosis or aggression after seizures.I cannot lie on my back for two hours.I have anemia caused by not having enough iron.My kidney function is reduced, with a GFR under 60.I am between 18 and 60 years old.I have epilepsy that hasn't improved with treatment for over a year, with at least one seizure a month.My seizure origin has been identified through standard tests.I have a history of serious liver or kidney disease.
- Group 1: 1
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there known adverse effects for using Mangafodipir therapeutically?
"In light of Mangafodipir's Phase 1 status, with limited evidence for safety and efficacy, our team assigned it an assessment score of 1."
What criteria must a person meet to be included in this research project?
"The study is open to 20 participants suffering from aura, with ages ranging between 18 and 60. Eligible individuals must meet the following prerequisites: Ages within 18-60 years old; drug resistant epilepsy as evidenced by consistent EEG findings according to the 1981 International Classification of Epileptic Seizures not responding well to anti-seizure treatments for at least a year before enrollment in this trial, including an average of one seizure per month; localization of seizures focus established via conventional clinical, neurophysiological and imaging studies; prior or concurrent participation in protocol 18-N-0066 handled through NINDS Clinical Epilepsy Service."
Are participants still being accepted for this clinical experiment?
"Indicated by clinicaltrials.gov, this trial is no longer recruiting patients; it was initially posted on November 6th 2023 and the most recent update to its profile occurred on November 22nd 2022. In spite of this particular study's closure, 249 other medical trials are actively searching for participants at present."
Has Mangafodipir been investigated in previous research?
"Currently, there is a single clinical trial actively studying the effects of mangafodipir. This Phase 3 study has not yet begun, however two locations in Bethesda Maryland are ready to open recruitment for this research."
How many subjects are actively engaging in the research endeavor?
"This research initiative is no longer seeking participants. The trial was posted on November 6th 2023 and last updated on November 22nd 2022. Currently, there are 248 clinical trials for aura patients that are still accepting members and one Mangafodipir study recruiting individuals as well."
Does this research protocol stipulate any age restrictions?
"This medical trial is open to any patient between 18 and 60 years of age. For those that fall outside this range, there are 105 clinical studies available for minors as well as 165 trials designed for seniors."
Share this study with friends
Copy Link
Messenger